Inhaled aztreonam lysine: An evidence-based review

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 15, 2013, Pages 2115-2124

  Hutchinson, David ^a,b   Barclay, Meghan ^b   Prescott, William A ^c   Brown, Jack ^a,b,c  

^a ST JOHN FISHER COLLEGE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Aztreonam lysine; Cystic fibrosis; Inhaled antibiotics; Nebulization; Pharmacodynamics; Pharmacokinetics; Pharmacology and safety

Indexed keywords

AZTREONAM LYSINE; CORTICOSTEROID;

CORTICOSTEROID THERAPY; COUGHING; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EMBASE; EVIDENCE BASED PRACTICE; FEVER; FORCED EXPIRATORY VOLUME; HEADACHE; HEALTH CARE COST; HEMOPTYSIS; HUMAN; LUNG DISEASE; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MICROBIOLOGY; NEBULIZER; NOSE OBSTRUCTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RHINORRHEA; SORE THROAT; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT INDICATION; WHEEZING;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; AZTREONAM; COSTS AND COST ANALYSIS; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 84884581928     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.831070     Document Type: Review

References (42)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373(9678):1891- 904
2. Patient Registry Annual Data Report 2011. Bethedsa, MD: Cystic Fibrosis Foundation, 2012
3. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293(5):581-8
4. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12(3):158-61
5. Emerson J, McNamara S, Buccat AM, et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010;45(4):363-70
6. Gruson D, Hilbert G, Vargas F, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003;31(7):1908-14
7. Pujol M, Gudiol F. Evidence for antibiotic cycling in control of resistance. Curr Opin Infect Dis 2001;14(6):711-15
8. CF Services Pharmacy Web Site. Available from: http://www. cfservicespharmacy.com/ProductsandPrices/CaystonAztreonam ForInhalationSolutionAndThe [Cited 13 June, 2013]
9. Assael B, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cystic Fibrosis 2013;2:130-40
10. Product Informtion. Cayston (aztreonam for inhalation solution). Gilead Sciences, Inc; Foster City, CA: 2012
11. Georgopapadakou NH, Smith SA, Sykes RB. Mode of action of aztreonam. Antimicrob Agents Chemother 1982;21(6):950-6
12. Kirkby S, Novak K, McCoy K. Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review. Core Evid 2011;6:59-66
13. Dietzsch HJ, Gottschalk B, Heyne K, et al. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 1975;55(1):96-100
14. Sapienza MA, Kharitonov SA, Horvath I, et al. Effect of inhaled L-arginine on exhaled nitric oxide in normal and asthmatic subjects. Thorax 1998;53(3):172-5
15. Gibson RL, Retsch-Bogart GZ, Oermann C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41(7):656-65
16. King P, Lomoskaya O, Griffith DC, et al. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 2010;54(1):143-8
17. Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009;53(9):3847-54
18. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011;9:32
19. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178(9):921-8
20. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45(11):1121-34
21. Retsch-Bogart GZ, Burns JL, Otto KL, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008;43(1):47-58
22. Shawar RM, MacLeod DL, Garber RL, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999;43(12):2877-80
23. FDA Anti-Infective Drugs Advisory Committee. Aztreonam for Inhalation Solution (NDA 50-814) for Improvement of Respiratory Symptoms in Cystic Fibrosis Patients. 2009
24. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135(5):1223-32
25. Product Information. AZACTAM (aztreonam for injection). Bristol-Myers Squibb; Princeton, NJ: 2010
26. Zeitler K, Salvas B, Stevens V, et al. Aztreonam lysine for inhalation: new formulation of an old antibiotic. Am J Health Syst Pharm 2012;69(2):107-15
27. Kuhn RJ. Formulation of aerosolized therapeutics. Chest 2001;120(3 Suppl):94S-8S
28. Prescribing information. Tobi (tobramycin for inhalation, USP). Novartis Pharmaceuticals Corp; East Hanover, NJ: 2009
29. Wainwright CE, Quittner AL, Geller DE, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. Journal of Cystic Fibrosis 2011;10(4):234-42
30. Tullis EBJ, Retsch-Bogart G, Bresnik M, et al. Aztreonam for inhalation solution (AZLI) in cystic fibrosis patients with chronic Burkholderia species (BURK) infection: inhitial results from a randomized, placebo-controlled trial (abstract 234). Pediatr Pulmonol 2011;46(Suppl 34):296
31. Oermann CM, McCoy KS, Retsch-Bogart GZ, et al. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother 2011;66(10):2398-404
32. Cayston Access Program. Available from: https://http://www.cayston.com/ caystonaccess-program.html [Cited 13 June, 2013]
33. Medi-Span. Available from: http://www. medispan.com/index.aspx [Cited 13 June, 2013]
34. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680-9
35. Cystic Fibrosis Foundation Patient Registry: annual data report 2011. Available from: http://www.cff.org/livingwithcf/qualityimprovement/ patientregistryreport [Cited 17 June, 2013]
36. Pesaturo KA, Horton ER, Belliveau P. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes. Ann Pharmacother 2012;46(7-8):1076-85
37. Hoiby N, Koch C. Cystic fibrosis. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 1990;45(11):881-4
38. Doring G, Flume PA, Heijerman H, et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2011;11(6):461-79
39. Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF (AZLI CAT). Available from: http:// clinicaltrials.gov/show/NCT01641822 [Cited 15July, 2013]
40. Aztreonam Lysine for Pseudomonas Infection Eradication Study (ALPINE). Available from: http://clinicaltrials.gov/show/NCT01375049
41. Schechter MS, Trueman D, Farquharson R, et al. An economic evaluation of aztreonam lysine for inhalation and tobramycin for inhalation, in anintermittent aerosolised antibiotic regime, among cystic fibrosis patients with chronic pulmonary pseudomonas AerugINOSa infection. Am J Respir Crit Care Med 2012;185:A6733
42. Cystic Fibrosis Foundation: drug development pipeline. Available from: http://www.cff.org/treatments/Pipeline Cited 14 June, 2013]